4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Osteoporosis
Interventions
DRUG

alendronate sodium (+) cholecalciferol

MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.

DRUG

Comparator: Placebo (unspecified)

MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00641771 - 4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230) | Biotech Hunter | Biotech Hunter